secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcturus Therapeutics Holdings Inc. (ARCT)
CIK:        0001768224
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001193805-24-000614
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcturus Q1 2024 revenue $38M, net loss $26.8M; Kostaive on track for Q3 launch, cash runway through FY2027
--------------------------------------------------------------------------------

- Q1 2024 revenue $38.0M (down 53% YoY); net loss $26.8M ($1.00/share) vs net income $50.8M ($1.87) in Q1 2023.
- Cash $345.3M; runway extends at least three years to Q1 FY2027; expects future CSL milestones.
- Kostaive commercialization on track: initial 4M doses delivery in Q3; European MAA decision expected Q3.
- Phase 3 pivotal study for ARCT-2303 (XBB.1.5) initiated; ARCT-2138 flu Phase 1 topline data expected Q3.
- ARCT-810 (OTC) and ARCT-032 (CF) data updates on July 1, 2024; JP Morgan engaged to monetize ARCALIS JV stake.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768224/000119380524000614/0001193805-24-000614-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768224/000119380524000614/e663590_8k-arct.htm
  HTML page:      https://secwatch.observer/filing/0001193805-24-000614

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer